Skip to main content

Table 3 Comparisons of CrAg positivity, incidence of CM and all-cause mortality among HIV-infected persons stratified by CD4+ T cell count

From: The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis

Author, yearPrevalence of CrAg positivityIncidence of CMAll-cause mortality
CD4<100 (cells/μL)CD4 100 ~ 200 (cells/μL)CD4<100 (cells/μL)CD4 100 ~ 200 (cells/μL)CD4<100 (cells/μL)CD4 100 ~ 200 (cells/μL)
with antifungal treatmentwithout antifungal treatmentwith antifungal treatmentwithout antifungal treatmentwith antifungal treatmentwithout antifungal treatmentwith antifungal treatmentwithout antifungal treatment
 Chariyalertsak, 2002 [25]Not reported0 of 406 of 450 of 230 of 21Not reportedNot reported
 Parkes-Ratanshi, 2011 [18]Not reported17 of 6982 of 8213a of 6980a of 821
 McKinsey, 1999 [19]Not reported0 of 1017 of 1031 of 481 of 43Not reportedNot reported
 Meya, 2010 [21]26 of 2957 of 2983 of 212 of 5Not reported6 of 215 of 50 of 41 of 3
 Govender, 2015 [1]20 of 7086 of 371Not reportedNot reportedNot reportedNot reported
 Borges, 2019 [24]12 of 1595 of 50 of 90 of 30 of 11 of 4Not reportedNot reported
 Pooled CrAg + prevalence:
0.06 [−0.02, 0.11], p = 0.001, I2 = 86.5%
Pooled CrAg + prevalence:
0.02 [0.01, 0.03], p = 0.146, I2 = 48%
Risk ratio with 95%CI:
7.67 [2.03, 29.05], p = 0.36, I2 = 1%
Risk ratio with 95%CI:
1.15 [0.16, 8.13],
p = 0.97, I2 = 0%
Risk ratio with 95%CI:
0.32 [0.16, 0.64], p and I2 not applicable
Risk ratio with 95%CI:
0.27 [0.01, 4.93], p and I2 not applicable
Risk ratio with 95%CI1.82 [0.77, 4.30], p = 0.007, I2 = 63%2.53 [0.50, 12.71], p = 0.26, I2 = 59%4.15 [0.89, 19.42], p = 0.07, I2 = 0%
  1. a Died within 4 weeks